MapLight Therapeutics Inc. shares jumped as much as 23% after the biotechnology firm raised $258.9 million in an initial ...

Inflammation biotech Evommune plans to take the leap into public waters with an expected initial public offering price of $15 ...

MapLight Therapeutics is heading to the Nasdaq this morning via a $250 million IPO the biotech will use to advance its ...

Evommune is set to make its stock market debut next week, but the biotech company is keeping investors guessing about its final share price.

The government shutdown has left the SEC quiet, but a Peninsula biotech managed to go public anyway, lighting a path to Wall ...

The China Securities Regulatory Commission (CSRC) issued new guidelines to reform the offline IPO placement mechanism, giving ...

New corporate brand reflects strategic transformation to a global biotech platform accelerating access to innovative ...

(Reuters) -MapLight Therapeutics debuted on the Nasdaq on Monday with a valuation of $787 million, becoming the first company ...

A well-crafted narrative helps investors see not just the molecule in front of them, but the broader therapeutic and ...

We’ve also seen investors lean into neurodegenerative and CNS conditions like schizophrenia. Karuna’s $14 billion acquisition ...

MapLight Therapeutics Inc. will raise $258.9 million in an initial public offering and private placement, becoming the first ...

Biotech insiders tout antibody-drug conjugates as the next big thing in cancer treatment, with firms urged to pursue global ...